Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer 1 , is characterized by elevated glycogen levels and fat deposition 2 . These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs) 3 secondary to von Hippel-Lindau (VHL) mutations that occur in over 90% of ccRCC tumours 4 . However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation 5 , suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others) 6-9 , indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) 10 is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients 11 . Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin 12 , thereby inhibiting a potential Warburg effect 13, 14 . Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalyticactivity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours 6, 7, 15 .
Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer 1 , is characterized by elevated glycogen levels and fat deposition 2 . These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs) 3 secondary to von Hippel-Lindau (VHL) mutations that occur in over 90% of ccRCC tumours 4 . However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation 5 , suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others) [6] [7] [8] [9] , indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) 10 is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients 11 . Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin 12 , thereby inhibiting a potential Warburg effect 13, 14 . Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalyticactivity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours 6, 7, 15 .
We performed pan-metabolomic analysis on 20 primary human ccRCC tumours and matching normal kidney tissues. Levels of metabolites involved in glycolysis, gluconeogenesis and glucose-related sugar metabolism were highly elevated in tumours, suggesting that reprogramming of glucose metabolism is critical for ccRCC progression (Extended Data Fig. 1a ). Furthermore, metabolic gene set analysis 16 of The Cancer Genome Atlas ccRCC RNA-sequencing data indicated that the carbohydrate storage group was the most significantly underexpressed gene set in ccRCC tumours (Fig. 1a ), including three genes controlling renal gluconeogenesis 17 (glucose-6-phosphatase, catalytic subunit (G6PC), phosphoenolpyruvate carboxykinase 1 (PCK1), and FBP1) (Extended Data Fig. 1b-c ). Elevated HIF activity in ccRCC tumours stimulates aerobic glycolysis by increasing the expression of glycolytic genes, including phosphoglycerate kinase 1 (PGK1) and lactate dehydrogenase A (LDHA), and shunting glycolytic flux away from the TCA cycle by activating pyruvate dehydrogenase kinase 1 (PDK1) 3 . However, our integrative analyses identified suppression of gluconeogenesis as an additional component of glucose regulation in ccRCCs. Next, we determined that the rate-limiting gluconeogenic enzyme FBP1 was inhibited at the level of protein accumulation in almost 100% of ccRCC tumours examined (n . 200, Fig. 1b and Extended Data Fig. 2a -c) compared to normal kidney tissue. Similar results were observed for hepatocellular carcinomas and normal liver tissue (Extended Data Fig. 2d, e ). FBP1 inhibition is not mediated by ccRCC-associated HIF activation, because HIF1A (that is, the mRNA that codes for HIF-1a) ablation failed to de-repress FBP1 expression in RCC4 ccRCC cells (Extended Data Fig. 2f ). Moreover, HK-2 cells, from proximal tubule epithelial cells (where ccRCCs appear to arise 12 ) exhibited HIF-1a-dependent induction of FBP1 under hypoxia (Extended Data Fig. 2g , h). Compared to FBP1, the other two gluconeogenic enzymes G6PC and PCK1 were either modestly suppressed (G6PC), or exhibited no consistent change (PCK1) in ccRCC tumours (Extended Data Fig. 3a, b) . Notably, the glycolytic enzyme phosphofructokinase (liver type, PFKL), which functionally antagonizes FBP1 in glycolysis (Extended Data Fig. 1c ), was expressed at equal levels in ccRCC and normal kidney tissues (Extended Data Fig. 3c ). In addition, lower FBP1 expression correlates significantly with advanced tumour stage and worse patient prognosis ( Fig. 1c, d) , whereas PFKL expression does not (Extended Data Fig. 3d, e ), suggesting that FBP1 may have novel, non-enzymatic function(s).
To investigate functional roles for FBP1 in ccRCC progression, we ectopically expressed FBP1 in 786-O ccRCC tumour cells to levels observed in HK-2 proximal tubule cells (Extended Data Fig. 4a ). FBP1 expression significantly inhibited 2D culture ( Fig. 1e ), anchorage-independent (Extended Data Fig. 4b ), and xenograft tumour growth ( Fig. 1f and Extended Data Fig. 4c ). Similarly, enforced FBP1 expression inhibited growth of RCC10 and 769-P ccRCC cells (Extended Data Fig. 4d , e) and A549 lung cancer cells preferentially under hypoxia (Extended Data Fig. 4f , g). These results demonstrate that FBP1 can suppress ccRCC and other tumour cell growth, an effect significantly pronounced when coupled with HIF activation. In HK-2 cells, FBP1 depletion, but not G6PC ablation or ectopic PFKL expression, was sufficient to promote HK-2 cell growth ( Fig. 1g and Extended Data Fig. 4h -j).
Since FBP1 is the rate-limiting enzyme in gluconeogenesis 10 , we manipulated FBP1 expression in renal cells and measured glucose metabolism. FBP1 inhibition increased glucose uptake and lactate secretion in HK-2 cells cultured in 10 mM glucose, ( Fig. 2a ), an effect augmented by lowering glucose levels to 1 mM (Extended Data Fig. 5a , b). To assess glycolytic flux, we performed isotopomer distribution analysis using [1,2-13 C]glucose as the tracer, which produces glycolytic and TCA intermediates containing two 13 C atoms (M2 species), as well as corresponding M1 species containing one 13 C atom from the pentose phosphate pathway (PPP; Extended Data Fig. 5c ). We observed elevated M2 enrichment of four TCA intermediates (malate, aspartate, glutamate and citrate) in FBP1-depleted HK-2 cells (Fig. 2b, c) . In contrast, G6PC inhibition failed to promote glucose-lactate turnover (data not shown), suggesting that FBP1, but not G6PC, is a critical regulator of glucose metabolism in renal cells. Consistent with this result, ectopic FBP1 expression in a VHL-deficient ccRCC cell line (RCC10) reduced glucose uptake, lactate secretion and glucose-derived TCA cycle intermediates ( Fig. 2d, e ). Reduced glucose-dependent TCA flux is known to increase anaplerotic glutamine flux 18 , and we also observed elevated glutamine uptake and enrichment of glutamine-derived TCA cycle intermediates (M4 species) in [U-13 C]glutamine-labelled RCC10 cells expressing FBP1 (Extended Data Fig. 5d-f ).
Pan-metabolomic analyses of ccRCC tumours revealed a marked elevation of reduced glutathione (G-SH) 19 (Extended Data Fig. 5g ). G-SH synthesis requires the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), generated primarily though the PPP in human cells 19 (Extended Data Fig. 5c ). Consistent with increased PPP flux, ccRCC tumours display significant accumulation of G-SH and PPP-related metabolites (Extended Data Fig. 5g ), an effect partially recapitulated in FBP1-depleted HK-2 cells (Extended Data Fig. 5h -j). Conversely, FBP1 re-expression in RCC10 cells significantly reduced NADPH levels and PPP flux ( Fig. 2f and Extended Data Fig. 5k, l) . Furthermore, FBP1mediated changes in PPP flux (Extended Data Fig. 5j and 5l) were comparable to the changes in glucose 6-phosphate (G6P; Extended Data Fig. 5m , n), the entry metabolite of the PPP pathway (Extended Data Fig.  5c ), suggesting that FBP1 affects PPP flux primarily through regulating glycolysis. Notably, the ability of FBP1 to reduce glycolysis and NADPH levels was completely abolished in RCC10-VHL cells (Fig. 2d, f) , that is, cells where wild-type pVHL was reintroduced into RCC10 cells to exclude normoxic HIF expression (Extended Data Fig. 5o ), indicating that HIF proteins are required for FBP1-mediated effects on glucose metabolism in ccRCC tumour cells.
To investigate a mechanistic link between FBP1 expression and HIF activity, we employed two VHL-deficient ccRCC lines, RCC4 and RCC10, which express both HIF-1a and HIF-2a (Extended Data Fig. 6a ). HIF-1a and HIF-2a are induced at different stages of ccRCC and have cooperating and contrasting roles in tumour progression 3 . HIF-1a and HIF-2a function by binding hypoxia response elements (HREs) within target genes, including those modulating cellular metabolism 20 . Notably, ectopic FBP1 expression suppressed HIF activity ( Fig. 3a ) and promoted oxygen consumption in RCC4 and RCC10 cells (Extended Data Fig. 6b , c). Furthermore, FBP1 expression in RCC10 cells restored pyruvate dehydrogenase activity (Extended Data Fig. 6d -f), which was otherwise inhibited by HIF-1a (ref. 3) . Conversely, FBP1 ablation enhanced HIF activity in RCC10 cells, which express detectable levels of FBP1 ( Fig. 3a and Extended Data Fig. 6a ). This inverse correlation between FBP1 expression and HIF activity was recapitulated in primary ccRCC tumours (Fig. 3b ). In 
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contrast, G6PC expression did not correlate with HIF activity in ccRCC cells or tumour tissues (Extended Data Fig. 6g , h). FBP1 also inhibited HIF activity in A549 lung cancer cells cultured at 0.5% O 2 (Fig. 3c ), demonstrating that this effect is not specific to renal cells. Moreover, FBP1 expression reduced canonical HIF target (PDK1, LDHA, glucose transporter 1 (GLUT1, also known as SLC2A1) and vascular endothelial growth factor (VEGF)) mRNA levels in RCC4, RCC10 and hypoxic A549 cells, but not in normoxic RCC10-VHL cells ( Fig. 3d and Extended Data Fig. 6i -k). Chromatin immunoprecipitation (ChIP) analyses indicated that FBP1 was enriched at the HREs of PDK1, LDHA, GLUT1 and VEGF promoters, but not at the promoter of ribosomal protein L13a (RPL13A), which is non-responsive to hypoxia ( Fig. 3e and Extended Data Fig. 7a ). ChIP-reChIP analyses revealed co-localization of HIF-1a and FBP1 at these HREs (Extended Data Fig. 7b ), suggesting that FBP1 directly inhibits HIF in the nucleus, a conclusion supported by cellular fractionation and immunofluorescent staining of primary human kidney tissue ( Fig. 3f and Extended Data Fig. 7c, d ). Furthermore, a nucleus-excluded form of FBP1 (FBP1(NES)) containing a potent nuclear export sequence 21 fused to the FBP1 carboxy terminus (Extended Data Fig. 7e ) failed to inhibit HIF target gene expression as efficiently as wild-type FBP1 (Extended Data Fig. 7f ). Expression of FBP1(NES) neither suppressed RCC10 cell growth nor altered glucose-lactate turnover, in contrast to wild-type FBP1 ( Fig. 3g and Extended Data Fig. 7g , h). Collectively, these data demonstrate that nuclear FBP1 is required for inhibiting HIF and glucose metabolism in VHL-deficient ccRCC cells (Extended Data Fig. 7i ).
To determine whether FBP1 enzymatic activity is required to inhibit HIF, we expressed a previously described, catalytically inactive FBP1(G260R) LETTER RESEARCH mutant 22,23 ( Fig. 4a and Extended Data Fig. 8a, b ) in RCC10 and 786-O cells (Extended Data Fig. 8a , c). FBP1(G260R) inhibited cell growth to a comparable level of wild-type FBP1 in 10 mM glucose ( Fig. 4b and Extended Data Fig. 8d ). FBP1(G260R) also inhibited glucose metabolism, NADPH production and HIF target gene expression to the same extent as wild-type FBP1 in RCC10 cells (Extended Data Fig. 8e-h) . These results suggest that FBP1 interferes with HIF function through a catalyticactivity-independent mechanism. In normoxic RCC10-VHL cells (low HIF activity), the ability of the FBP1(G260R) mutant to inhibit cell growth, glucose metabolism, NADPH production and HIF target gene expression was abolished (Extended Data Fig. 8c , i-m), further confirming that FBP1 impacts ccRCC cell metabolism and growth by regulating HIF, independent of its enzymatic activity. Nevertheless, wild-type FBP1 suppressed RCC10 and 786-O (Extended Data Fig. 9a , b) cell growth more potently than the G260R mutant under low-glucose conditions, presumably because the enzymatic inhibition of glycolysis by wild-type FBP1 is more profound when glucose supply becomes limited. To explore the molecular mechanism(s) whereby FBP1 inhibits HIF activity, we separated the FBP1 protein into an N-terminal regulatory (R) domain containing allosteric regulatory sites and a C-terminal (C) domain containing the catalytic site ( Fig. 4a) . Notably, ectopically expressing the FBP1 R domain in RCC10, RCC4 and 786-O cells was sufficient to inhibit HIF activity, whereas expressing the C domain was not ( Fig. 4c and Extended Data Fig. 9c, d) . As 786-O cells express HIF-2a but not functional HIF-1a (ref. 24) , we conclude that FBP1 inhibits both HIF-1a and HIF-2a, presumably through a similar mechanism. To further map critical FBP1 regions for HIF recognition, we systematically deleted each exon from full-length FBP1 (Extended Data Fig. 9e ). All seven FBP1 truncations exhibited minimal catalytic activity (Extended Data Fig. 9f ), whereas only the N-terminal exon 1 and exon 2 truncations significantly lost their ability to inhibit HIF (Extended Data Fig. 9g ).
We further demonstrated the association of FBP1 and HIF-1a by co-immunoprecipitating epitope-tagged and/or endogenous proteins from 293T or RCC10 cell lysates ( Fig. 4d and Extended Data Fig. 9h , i). FBP1 also associated with HIF-2a ( Fig. 4e and Extended Data Fig. 10a , b), but not with PHD2 or FIH1, two well-documented HIF-a regulators 3 (Extended Data Fig. 10c ). Interestingly, GST pull-down assays revealed that HIF-1a or HIF-2a proteins bound directly to full-length FBP1 ( Fig. 4f and Extended Data Fig. 10d ), and the interaction between HIF-1a and FBP1 is dependent on FBP1 exon 1 or exon 2 (Fig. 4g ). Furthermore, FBP1 associates with the relatively uncharacterized HIF inhibitory domain 25 (Fig. 4h and Extended Data Fig. 10e ). To examine whether FBP1 inhibits HIF activity through inhibitory domain recognition, we replaced the HIF-a DNA binding domain with a GAL4 DNA binding domain (GBD) and performed GAL4 transactivation assays (Extended Data Fig. 10e ). Consistent with HIF reporter assays (Figs 3a, c, 4c and Extended Data Fig. 9g ), FBP1 suppressed full-length HIF-1a(GBD) activity by approximately 50% (Extended Data Fig. 10f , red column). Importantly, removal of the HIF-1a inhibitory domain largely relieved the FBP1 inhibitory effect (Extended Data Fig. 10f ). In HIF-2a, the critical region mediating FBP1 inhibition extended to the entire C terminus (Extended Data Fig. 10g ). Therefore, FBP1 suppresses HIF-1a and HIF-2a activity by interacting with their C-terminal regions, especially the inhibitory domain motif.
Apart from VHL loss, ccRCCs exhibit remarkable genetic heterogeneity 26 . Recent large-scale analyses identified frequent mutations in three epigenetic genes -PBRM1, SETD2 and BAP1 -all of which reside in a 43-megabase region on chromosome 3p that encompasses VHL (refs 6-9). Histologically, ccRCC is characterized by the clear-cell phenotype resulting from glycogen and lipid accumulation 2 , suggesting that metabolic perturbations are a defining feature of these tumours. Here we demonstrate that the gluconeogenic enzyme FBP1 is ubiquitously depleted in ccRCCs, consistent with our previous copy number analyses 27 . Moreover, FBP1 exhibits dual tumour-suppressive functions mediated by two separate domains, explaining the universal loss of FBP1 expression in ccRCC tumours. Collectively, our data reveal an intriguing regulatory relationship between FBP1 and hypoxic responses in renal carcinoma, which has implications for the metabolic regulation of all gluconeogenic tissues (Supplementary Discussion).
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METHODS Antibodies and reagents. Antibodies detecting HDAC1 (5356), HSP90 (4877), GST (2625), HA (3724), and normal IgG isotopic controls (rabbit-2729, mouse-5415) were purchased from Cell Signaling Technology. Antibodies detecting HIF-1a (NB100-134) and HIF-2a (NB100-122) were obtained from Novus, and antibodies against PCK1 (ab28455), G6PC (ab83690), and PFKL (ab37583) were from Abcam. D-fructose-1,6-bisphosphate trisodium salt (47810), 2-hydroxyethyl agarose (A4018), and antibodies detecting FBP1 (SAB1405798 and HPA005857) were purchased from Sigma. Cell culture. 786-O, RCC4, RCC10, 769-P, A549 and 293T cells were tested to confirm they are mycoplasma negative, and cultured in DMEM containing 10% FBS and antibiotics. HK-2 proximal tubular epithelial cells were cultured in Keratinocyte-SFM medium supplemented with human recombinant epidermal growth factor 1-53 and bovine pituitary extract (Life Technologies). Hypoxic conditions (0.5% O 2 ) were achieved in a Ruskinn in vivo2 400 workstation, by supplementing ambient air with balanced N 2 and CO 2 . For metabolic labelling assays, cells were maintained in glucose-free DMEM (Life Technologies) supplemented with 10% dialysed FBS (Gemini Bio Products) and 10 mM [1,2-13 C]glucose (Cambridge isotope), or glutaminefree DMEM (Life Technologies) supplemented with 10% dialysed FBS and 2 mM [U-13 C]glutamine (Cambridge isotope).
Constructs. An HRE (hypoxia response element) reporter construct was generated by introducing triplicate HRE motifs derived from the human PGK1 promoter in front of a luciferase expression cassette in the pGL2-TK vector. shRNA plasmids targeting human FBP1, G6PC and HIF1A mRNAs were purchased from Open Biosystems. The antisense short-hairpin sequences against human FBP1 are 59-ATGTTGGAAGATCCATCAAGG-39 (SH-1) and 59-AACATGTTCATAACC AGGTCG-39 (SH-2). The antisense sequence against human G6PC is 59-TTCAAG GAGTCAAAGACGTGC-39, and sequences against human HIF1A are 59-TAAC TTCACAATCATAACTGG-39 (SH-1) and 59-ATTCGGTAATTCTTTCATCAC-39 (SH-2). FBP1, G6PC and PFKL expression plasmids were constructed by cloning the open reading frame of each cDNA into the multiple cloning site of PCDNA3.1-V5 vector. The FBP1(G260R) mutant was generated using Stratagene's QuikChange II mutagenesis Kit (Agilent). FBP1(NES) was generated by linking an efficient nuclear export sequence (LALKLAGLDIGS) to the FBP1 C terminus of its expression cassette. (1-275). Full-length FBP1, HIF-1a, and HIF-2a were cloned into the pGEX-6P-1 vector to create GST-tagged protein constructs. Various GST-tagged HIF-1a motifs were generated by subcloning the following regions from full-length HIF-1a (1-826) into the pGEX-6P-1 vector: bHLH (1-80), PASA (81-235), PASB (236-329), LINK (330-392), NODD (393-531), NTAD (532-603), ID (604-786), CTAD (787-826). For GAL4 transactivation assays, HIF-a sequences lacking the bHLH DNA binding motif were cloned into the pBIND vector (Promega), which is in frame with a GAL4 DNA binding domain (GBD) at the N terminus. A series of GBD-HIF-1a truncations were created by removing indicated HIF-1a motifs. Similarly, GBD-HIF-2a truncations were generated by individually deleting the following motifs from HIF-2a sequences (1-870): PASA (80-236), PASB (237-331), LINK (332-395), NODD (396-495), NTAD (496-581), ID (582-830), CTAD (831-870). GFP-FIH1 and GFP-PHD2 constructs were obtained from E. Metzen via Addgene. Plasmid transfection and virus infection. Expression constructs were transfected into cancer cell lines using Lipofectamine LTX reagent (Life Technologies) by following the manufacturer's protocol. Lentivirus was produced by co-transfecting 293T cells with pRSV-Rev, pMD2.G, pMDLg/pRRE, and pLKO.1-puro shRNA or pCDH-puro expression vectors. Virus was harvested after 48 h by filtering the viruscontaining medium through 0.45 mm Steriflip filter (Millipore). Virus infection was performed by incubating cells with medium containing indicated virus and 8 mg ml 21 polybrene (Sigma) for 24 h. Cells were allowed to recover in complete medium for 24 h and then selected with puromycin for 24 h (mRNA analysis) or 48 h (protein and phenotypic analyses). Surviving pools were subjected to indicated experiments. Note that HK-2 cells undergoing virus infection and puromycin selection typically need 10-14 days recovery time before subjected to experiments. TCGA RNA-seq analysis. Raw RNA-seq data for 480 ccRCC tumour and 69 normal kidney tissues were downloaded from the TCGA ccRCC project (http://cancergenome. nih.gov) on 2 April 2013. Data was analysed for differential gene expression using DeSeq (Bioconductor Version 2.12). Normalized counts, P values, false discovery rateadjusted P values (p-adj), and fold expression change for each gene were exported. To perform the gene set analysis, a comprehensive list of 2,752 genes encoding all known human metabolic enzymes and transporters were clustered into functional sets according to the metabolic pathways annotated by the Kyoto Encyclopaedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/). The cut-off value of p-adj was set to 0.1 to exclude genes not consistently detected by RNA-seq. To examine tumour-associated HIF activities, raw data of each sequenced gene were rescaled to set the median equal to 1, and HIF activities were quantified by averaging the normalized expression of 44 HIF target genes including those encoding IGFBP3,  EDN2, PFKFB4, FLT1, TFR2, BNIP3L, TGFA, BNIP3, PGK1, EGLN1, LDHA,  EGLN3, CP, TGFB3, PFKFB3, HK1, TFRC, EDN1, CDKN1A, CA9, ADM1, HMOX1,  SERPINE1, LOX, NDRG1, CA12, PDK1, VEGFA, ERO1L, RORA, P4HA1, MXI1,  SLC2A1(GLUT1), STC2, MIF, DDIT4, ENO1, CXCR4, PLOD1, P4HA2, GAPDH,  PGAM1, TMEM45A and PIM1 (ref. 28 ). Metabolite quantification. The rate of glucose uptake and lactate secretion was determined using a YSI 7100 Multiparameter Bioanalytical System (YSI Life Sciences). NAPDH levels were measured using NADP 1 /NADPH Quantification Kit (BioVision) by following the manufacturer's protocol. Glucose 6-phosphate (G6P) levels were determined using PicoProb G6P Fluorometric Assay Kit (BioVision) by following the manufacturer's protocol. Absolute NADPH or G6P levels were normalized to vector control cells by setting the vector control levels equal to 1. Pan-metabolomic analysis was performed on 20 primary ccRCC tumours and 20 adjacent normal kidney tissues (obtained from Cooperative Human Tissue Network) with the assistance of Metabolon. Specifically, sample preparation was carried out using the automated MicroLab STAR system (Hamilton). Standards were added before the first extraction step for quality control purposes. Metabolite extracts were divided into two fractions: one fraction was analysed by a gas chromatography-mass spectrometer (GC-MS) and the other by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Samples for GC-MS analysis were dried under vacuum desiccation for 24 h before derivatization under nitrogen with bistrimethyl-silyl-triflouroacetamide (BSTFA) treatment. The GC column was 5% phenyl and the temperature ramp was from 40 to 300 uC in a 16-min period. Samples were analysed by a Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact ionization. The LC-MS/ MS portion of this analysis was based on a Waters ACQUITY UPLC and a Thermo-Finnigan LTQ mass spectrometer, which consists of an electrospray ionization (ESI) source and linear ion-trap (LIT) mass analyser. Sample extracts were split into two aliquots, dried, and reconstituted separately in acidic or basic solvents. One aliquot was analysed in acidic positive ion optimized conditions and the other in basic negative ion optimized conditions using dedicated columns. Extracts reconstituted in acidic conditions were gradient eluted using water and methanol containing 0.1% formic acid, while the basic extracts were eluted using water and methanol containing 6.5 mM ammonium bicarbonate. The MS analysis alternated between MS and MS/MS scans using dynamic exclusion. Compounds were identified by comparison to an in-house metabolomic library with purified standards. More than 3,000 commercially available standard compounds have been registered for determination of their analytical characteristics. The combination of chromatographic properties and mass spectra gave an indication of a match to a specific compound or an isobaric entity. For studies spanning multiple days, a data normalization step was included to correct variation resulted from instrumental tuning differences. To generate the end report, raw data of each metabolite were rescaled to set the median equal to 1. For pair-wise comparison of pentose phosphate pathway-related metabolites, Welch's t-tests were performed. A q value is also reported to describe the false discovery rate in multiple testing. 13 C-metabolic flux analysis. To measure the 13 C enrichment in TCA cycle intermediates, [1,2-13 C]glucose-labelled (48 h at 37 uC) or [U-13 C]glutamine-labelled cells (3 h at 37 uC) were extracted by 4% perchloric acid (PCA) as previously described 29 . Briefly, cells were washed twice with PBS and then incubated with 4% PCA for 30 min at 4 uC on a rocking platform. Cell extracts were collected and neutralized using 5 M KOH. After centrifugation, supernatants were subjected to an AG-1 column (100-200 mesh, 0.5 3 2.5 cm, Bio-rad) for enriching the organic acids, glutamate and aspartate, which were then converted to t-butyldimethylsilyl derivatives. Isotopic enrichment in [ 13 C]glutamate isotopomers was monitored using ions at m/z 432, 433, 434, 435, 436 and 437 for M0, M1, M2, M3, M4 or M5 (containing 1 to 5 13 C atoms above M0, the natural abundance), respectively. Isotopic enrichment in [ 13 C]aspartate isotopomers was monitored using ions at m/z 418, 419, 420, 421 and 422 for M0, M1, M2, M3 and M4 (containing 1 to 4 13 C atoms above M0, the natural abundance), respectively. Isotopic enrichment in [ 13 C]lactate was determined using ions at m/z 261, 262, 263 and 264 for M0, M1, M2 and M3 (containing 1 to 3 13 C atoms above natural abundance), respectively. Isotopic enrichment in [ 13 C]pyruvate isotopomers was monitored using ions at m/z 259, 260, 261and 262 for M0, M1, M2 and M3 (containing 1 to 3 13 C atoms above natural abundance), respectively. Isotopic enrichment in [ 13 C]malate isotopomers was evaluated using ions at m/z 419, 420, 421, 422 and 423 for M0, M1, M2, M3 and M4 (containing 1 to 4 13 C atoms above natural abundance), respectively, and 13 C enrichment in [ 13 C]citrate isotopomers was assayed using ions at m/z 459, 460, 461, 462, 463, 464 and 465 for M0, M1, M2, M3, M4, M5 and M6 (containing 1 to 6 13 C atoms above natural abundance), respectively. Isotopic enrichment in [ 13 C]ribose 5-phosphate isotopomers was determined using a LC-MS system as previously described 29 . For ribose in MRM mode, we measured ion-pairs 561-175, 562-175, 563-175, 564-175, 565-175 and 566-175
for determination of M0, M1, M2, M3, M4 and M5, respectively (containing 1 to 5 13 C atoms above natural abundance). Quantification of the pentose phosphate pathway. Metabolic flux going through the pentose phosphate pathway (PPP) was quantified based on a previously described method 30 , using [1,2-13 C]glucose as the labelling tracer. Briefly, direct glycolysis of [1,2-13 C]glucose (without going through the PPP) produces M2-labelled lactate, while flux going through the oxidative portion of PPP removes the first carbon from glucose and releases it in the form of CO 2 . The resultant M1-labelled intermediates are recycled back to glycolysis to produce M1-labelled lactate through the nonoxidative potion of PPP. The ratio of M1 to M2-labelled lactate indicates the ratio of flux going through the PPP versus flux directly going through glycolysis. Therefore, PPP flux was calculated based on the following formula: PPP flux 5 glucose consumption rate (measured by YSI analyser as described above) 3 M1 lactate enrichment / (M1 lactate enrichment 1 M2 lactate enrichment). Calculated PPP flux was then normalized to vector control cells by setting the vector control flux equal to 1. An important assumption for this model is that most PPP-generated M1 intermediates are recycled back to glycolysis, rather than exported for nucleotide synthesis 30 . We have measured the isotopic distribution of ribose 5-phosphate using LC-MS and found that the enrichment of M1-labelled ribose 5-phosphate was undetectable, confirming that most M1-labelled intermediates generated in PPP were recycled back to glycolysis. Cell growth assay. Multiple cultures of ccRCC or A549 cells were plated in 6-well dishes at a density of 5 3 10 4 cells per well supplemented with DMEM containing 1% FBS. For growth assays performed in low-glucose conditions, cells were maintained in glucose-free DMEM supplemented with 10% dialysed FBS and 1 mM glucose. Each day one set of cultures was collected and counted. Anchorage-independent growth assay. 786-O cells stably expressing FBP1 and vector control 786-O cells were plated at a density of 6 3 10 3 cells per ml in complete medium containing 0.3% agarose, onto underlays composed of medium containing 0.6% agarose. Cultures were fed every week, and after three weeks of growth the colonies were quantified. Immunoprecipitation and western blot analysis. Cells were lysed with mammalian cell lysis buffer consisting of 25 mM Tris, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO 4 , 1 mM b-glycerol phosphate, and protease inhibitor cocktail (Roche Diagnostics). For immunoprecipitation experiments, cells were harvested in lysis buffer containing 0.3% CHAPS instead of 1% Triton X-100 as the detergent. 2 mg whole cell lysates were pre-cleared with 30 ml protein G beads (Life Technologies), and then incubated with 2 mg isotype-matched IgG control or indicated antibodies for 2 h on a rocking platform. 50 ml protein G beads were added and mixed for another 2 h. The immunoprecipitates were collected by centrifugation and then resolved by SDS-PAGE. Separated proteins were transferred to nitrocellulose membranes and the filters incubated with indicated primary antibodies diluted in TBST (20 mM Tris, 135 mM NaCl, and 0.02% Tween 20) supplemented with 5% bovine serum albumin (Sigma). Primary antibodies were detected with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) followed by exposure to ECL reagents (Pierce). Quantitative RT-PCR. Total RNA was isolated from cells using the RNAeasy purification kit (Qiagen). cDNA was synthesized using a High Capacity RNA-to-cDNA Master Mix from Applied Biosystems. qRT-PCR analysis was performed using TaqMan Universal PCR regents mixed with indicated cDNAs and TaqMan primers in an ViiA7 Real-Time PCR system (Applied Biosystems). Pre-designed TaqMan primers were obtained from Applied Biosystems detecting the following genes: FBP1 (ID: Hs00983323_m1), HIF1A (ID: Hs00153153_m1), PDK1 (ID: Hs01561850_m1), LDHA (ID: Hs00855332_g1), GLUT1 (SLC2A1, ID: Hs00892681_m1), VEGF (VEGFA, ID: Hs00900055_m1), 18S (RN18S1, Hs03928985_g1). Chromatin immunoprecipitation (ChIP) and ChIP-reChIP assay. ChIP assays were performed using Imgenex QuikChIP kit (Novus). Briefly, three million RCC10 cells stably expressing V5-FBP1 were cross-linked by 1% formaldehyde for 15 min at 37 uC. The cross-linking reaction was quenched by glycine and cells were lysed in SDS buffer containing protease inhibitor cocktail. Cell lysates were sonicated to shear chromatin DNA into fragments with 200-1,000 base pairs in size and then subjected to immunoprecipitation with 5 mg IgG (Cell Signaling Technology), V5 (Life Technologies), or Polymerase II (Imgenex) antibodies. After washing with a series of low-salt and high-salt washing buffers, immunoprecipitated DNA fragments were de-crosslinked at 65 uC in high-salt condition, purified using QIAquick PCR purification kit (Qiagen), and then analysed by qRT-PCR. For ChIP-reChIP assays, the first ChIP was performed using HIF-1a antibody (5 mg, Novus), until the washing steps. The immunoprecipitated protein-DNA complexes were incubated in ChIP-reChIP elution buffer (10 mM Tris, 1 mM EDTA, 2% SDS, and 20 mM DTT, pH 7.5) for 30 min at 37 uC. After centrifugation, the isolated supernatant was diluted at least 20 times and subjected to the second ChIP using 5 mg IgG or V5 antibodies. In both ChIP and ChIP-reChIP assays, qRT-PCR was performed using the following primers: PDK1-HRE: 59-CGCGTTTGGATTCCGTG-39 and 59-CCAGTTATAATC TGCCTTCCCTATTATC-39; LDHA-HRE: 59-TTGGAGGGCAGCACCTTACTT AGA-39 and 59-GCCTTAAGTGGAACAGCTATGCTGAC-39; GLUT1-HRE: 59-C AAATGTGTGGATGTGAGTTGC-39 and 59-CCATCACGGTCCTTCTTCATG-39; VEGF-HRE: 59-CAGGAACAAGGGCCTCTGTCT-39 and 59-GCACTGTGGAGTC TGGCAAA-39; RPL13A-nonHRE: 59-GAGGCGAGGGTGATAGAG-39 and 59-AC ACACAAGGGTCCAATTC-39. Luciferase reporter and GAL4 transactivation assay. 0.5 mg of HRE reporter construct was transfected into cells grown in 6-well plates together with 0.05 mg Renilla luciferase and 1 mg indicated expression or shRNA plasmids. Luciferase activities were measured 48 h later using Dual Luciferase assay kit (Promega). Reporter luciferase activities were normalized to Renilla luciferase, and then rescaled to set the vector control signals equal to 1. In GAL4 transactivation assay, 0.3 mg GBD-HIF-a construct (using pBIND vector as backbone) was transfected into 769-P (GBD-HIF-1a) or A549 (GBD-HIF-2a) cells together with 0.3 mg UAS (Upstream Activation Sequence)-luciferase reporter and 0.4 mg indicated expression plasmids. Luciferase activities were measured as described above. Transfection efficiencies were normalized to Renilla luciferase expressed from the pBIND backbone. Subcellular fractionation. Cytosolic and nuclear fractionation of indicated cells and tissues were performed using NE-PER nuclear and cytoplasmic extraction reagents (Pierce) by following the manufacturer's protocol. Enzymatic activity assay. 20 mg lysates of vector control 293T cells, or 293T cells expressing FBP1 or FBP1(G260R) were added to 100 ml reaction buffer containing 50 mM Tris, 10 mM MgCl 2 , and 100 mM D-fructose 1,6-bisphosphate trisodium salt. The reaction was started by incubating solutions at 37 uC for 15 min and stopped by a deproteinization protocol using deproteinizing sample preparation kit (BioVision). FBP1 catalytic activity was quantified according to the yield of fructose 6-phosphate (enzymatic product), measured by using PicoProb fructose-6-phosphate fluorometric assay kit (BioVision). Oxygen consumption assay. Vector control or FBP1-expressing RCC4 or RCC10 cells were seeded into black opaque 96-well plate at a density of 70,000 cells per well. After attachment, culture medium within each well was replaced with 150 ml oxygenated fresh medium, supplemented with 10 ml MitoXpess probe solution (Cayman Chemical). Antimycin A was used as negative control. 100 ml mineral oil was dispensed to overlay each well, and the whole plate was monitored using SpectraMax m2e microplate reader (Molecular Devices) at 37 uC. Wavelengths are set to 380 nm for excitation and 650 nm for emission. Protein purification. Constructs encoding indicated GST-tagged proteins were transformed into BL21-DE3 chemically competent Escherichia coli (Life Technologies), grown in rocking LB media at 37 uC to an OD600 value of 0.8. Protein expression was induced by adding 1 mM IPTG (Denville Scientific) to the LB cultures, which were rocked at 37 uC for another 3 h or at room temperature overnight. After centrifugation, collected bacterial pellets were resuspended in STE buffer (50 mM Tris, 150 mM NaCl, and 1 mM EDTA) supplemented with protease inhibitor cocktail (Sigma). GST-tagged proteins were further purified using the GST inclusion body solubilization and renaturation kit (Cell Biolabs) by following the manufacturer's protocol. GST pull-down assay. Assay was performed using GST Protein Interaction Pull-Down Kit (Pierce) by following the manufacturer's protocol. Breifly, 100 mg indicated GST-tagged 'bait' proteins were incubated with 50 ml prewashed glutathione agarose (Pierce) in 500 ml GST pull-down buffer (20 mM Tris, 150 mM NaCl, 2 mM MgCl 2 , 0.1% NP-40, and 20 mg ml 21 BSA) for 1 h at 4 uC. Meanwhile, 50 mg indicated 'prey' proteins was precleared with 50 ml prewashed glutathione agarose in 500 ml GST pull-down buffer for 1 h at 4 uC. Precleared 'prey' solutions were combined with the 'bait-agarose' solutions and mixed for another 2 h at 4 uC. Protein-bound agarose was washed 3 times and boiled in SDS sample buffer. Supernatants were subjected to SDS-PAGE and western blot analysis. Tissue immunohistochemistry and immunofluorescence. Normal kidney tissue sections (from Cooperative Human Tissue Network) and tissue microarray slides (KD801, KD208, BC07114, BC07115, LV804, and LV208 from US Biomax) were deparaffinized by baking slides at 60 uC for 30 min. The slides were rehydrated in series of ethanol solutions and endogenous peroxidase activities were quenched by 3% H 2 O 2 in distilled water for 30 min. After three washes in TT buffer (500 mM NaCl, 10 mM Trizma, and 0.05% Tween-20), antigen retrieval was performed by boiling slides for 20 min in a citrate-based antigen unmasking solution (Vector Labs). After cooling down to room temperature, slides were incubated with 4% normal goat serum in TT buffer for 1 h, and then blocked with avidin and biotin solutions (avidin/biotin blocking Kit, Vector Labs). Next, tissue slides were incubated with various primary antibodies at 4 uC overnight. After three washes in TT buffer, biotinylated secondary antibody was added onto these slides for 1 h, following by 1 h treatment of ABC reagents (Vectastain ABC Kit, Vector Labs). After three TT washes, the slides were processed with either chromogen (ImmPACT DAB Substrate, Vector Labs) and haematoxylin solutions for immunohistochemistry staining, or with Alexa Fluor 488 tyramide (TSA Kit #22, Life Technologies) for LETTER RESEARCH immunofluorescent experiments. Finally, slides were either dehydrated and mounted with paramount solution (for immunohistochemistry), or directly mounted with ProLong Gold antifade reagents (Life Technologies) supplemented with DAPI (for immunofluorescence). Animal studies. Xenograft tumour experiments were approved by the Animal Care and Use Committee at the University of Pennsylvania. Briefly, five female NIH-III nude mice (Charles River, 4-6 weeks) were injected subcutaneously into both flanks with five million vector control 786-O cells, or 786-O cells stably expressing FBP1. Before each injection, cells were resuspended in 150 ml DMEM mixed with an equal volume of matrigel (BD Bioscience). Once palpable tumours were established, tumour size was measured once a week with a digital calliper. After 4 weeks mice were killed by CO 2 inhalation, and xenograft tumours were dissected and weighed. Randomization and blinding are not applicable in this experiment. Human subjects. Primary human kidney samples were obtained from the Cooperative Human Tissue Network and handled at the University of Pennsylvania with the approval of its institutional review board committees. All tissues are collected with the donor being informed and given consent. Related procedures were performed in accordance with ethical and legal standards. Survival analysis. Available patient survival data were obtained from TCGA ccRCC project. Patients were ranked based on their tumour expressions of indicated genes shown in TCGA RNA-seq data. The top half of ranked patients was defined as the 'top 50% expression' group and the lower half was defined as the 'bottom 50% expression' group. Kaplan-Meier survival analyses and log-rank significance tests were performed on these two patient groups accordingly. Statistics. All results reported in main and Extended Data figures are presented as mean 6 s.d. unless otherwise specified. Data were reported as biological replicates except in qRT-PCR assays, where technical replicates from a representative experiment were used. Data beyond two standard deviations from the mean are treated as outliers. P values were calculated based on two-tailed, unpaired Student's t-tests. P , 0.05 was considered statistically significant. Extended Data Figure 5 | FBP1 regulates glycolysis, glutamine metabolism, and pentose phosphate pathway (PPP) in renal cells. a, b, Glucose uptake (a) and lactate secretion (b) in HK-2 cells with or without FBP1 inhibition, cultured in medium containing 1 mM glucose. c, Carbon fate map showing the isotopomer distribution of indicated metabolites derived from [1,2-13 C]glucose. 13 C atoms are depicted as filled circles. 13 C atoms directly going through the glycolytic pathway are coloured in black, while 13 C atoms going through the PPP and recycled back to glycolysis are coloured in red. d, Glutamine uptake in vector control or FBP1-expressing RCC10 cells. e, Carbon fate map showing the isotopomer distribution of indicated metabolites derived from [U- 13 C]glutamine. f, M4 isotopomer distribution of indicated metabolites in vector control or FBP1-expressing RCC10 cells, labelled with [U-13 C]glutamine. % M4 enrichment represents the mole per cent excess of M4 species above natural abundance. g, Fold changes of PPP-related metabolites detected in ccRCC tumours vs adjacent normal kidney. Note that generation of reduced glutathione (G-SH) requires NADPH, a major reducing product of PPP. P value is calculated based on Welch's paired t-test. q value is the estimation of false discovery rate in multiple testing. h, Relative NADPH levels in HK-2 cells with or without FBP1 inhibition. i, M1 and M2 isotopomer distribution of lactate in HK-2 cells with or without FBP1 inhibition. j, Calculated PPP flux (relative to vector control) in HK-2 cells with or without FBP1 inhibition. k-n, M1 and M2 isotopomer distribution of lactate (k) and calculated PPP flux (l) in vector control or FBP1-expressing RCC10 cells. Relative glucose 6-phosphate (G6P) levels in HK-2 cells with or without FBP1 ablation (m), and in vector control or FBP1-expressing RCC10 cells (n). o, Western blot analysis of indicated proteins in vector control or FBP1expressing RCC10 and RCC10-VHL cells. Experiments were performed in triplicates. Values represent mean 6 s.d. *P , 0.05.
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